Kingworld Brand Ranking
If you want to improve the ranking of your company brand or wish to avoid appearing here, please contact trading@bossgoo.com.
Kingworld

Kingworld

Shenzhen Goldenway Pharmaceutical Co., Ltd.
If you want to improve the ranking of your company brand or wish to avoid appearing here, please contact trading@bossgoo.com.
Brand Introduction

Kingworld brand , a well-known injury medicine brand, mainly include Jinhuoyimadazheng safflower oil and Feiyinghuoluo oil products. Jinhuo Pharmaceutical Group was established in Shenzhen in 1996 and was listed on the main board of the Hong Kong Stock Exchange in 2010 with the stock code 01110. Over the past 20 years, Jinhuo Pharmaceutical Group has adhered to the business philosophy of being proactive and sincere, and has continuously provided safe and effective medical and health products and services to customers around the world, forming a combination of brand agency, cross-border e-commerce, and Chinese medicine products. R&D, medical device production and investment in the big health industry are diversified and co-productive business entities. Currently, the business areas are spread across more than 34 provinces, cities, Hong Kong and Macao and online channels across the country.

The health products sold by the group include: Hong Kong Kyoto Nianci Pills, Hong Kong's Kyoto Milien Chuanbei Loquat Paste, Laba Brand Zhenglu Pills, Jinhuo Yima Dazheng Safflower Oil, Kangcui Le Probiotics, CARMEX Lip Balm Series, etc., to build a series of consumers. The Bridge of Health provides logistics management services, B2C trade services, data services and supply chain financial services to the world's advanced major core medical and health suppliers, manufacturers and distributors.

To adapt to the new normal of consumption upgrading, Jinhuo integrates new online marketing models with offline channels to better serve consumers and provide them with professional services for smart home health management, and build Jinhuo’s online and offline new retail ecosystem. In 2015, Jinhuo Pharmaceutical Group acquired 55% of Dongdixin Technology's equity, entered the global medical and health electronics market, and expanded the field of big health. In addition, it also established strategic cooperation with Sinopharm Capital to integrate resources between the two parties to make it bigger and stronger.

In the future, Jinhuo Pharmaceutical Group will always adhere to the corporate mission of "serving the world and nourishing the people", and continue to be committed to becoming a leading internationally renowned medical and health product service provider in China, and strive to build a harmonious and beautiful life community.

版权所有 © 宁波全贸信息技术有限公司 浙ICP备12012821号-1 浙B2-20200628

浙公网安备 33020902000078号